ReviewWorld journal of nephrology2014
Metabolic syndrome and chronic kidney disease: Current status and future directions.
Review in World journal of nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03321942 (The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure), which is not on this map. Cited by 75 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure
Who cites it
75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 163 citations in OpenAlex.
- Prevalence of metabolic syndrome in patients with end-stage renal disease: a systematic review and meta-analysis.International urology and nephrology · 2024Pooled it
- Anthocyanins-rich interventions on oxidative stress, inflammation and lipid profile in patients undergoing hemodialysis: meta-analysis and meta-regression.European journal of clinical nutrition · 2023Pooled it
- Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research.CNS drugs · 2022Pooled it
- The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.International urology and nephrology · 2018Pooled it
- Trial
- Incorporating dietary information to enhance polygenic prediction models with applications to body mass index and type 2 diabetes.Genes & nutrition · 2026Article
- Article
- Integrated genomics and metabolomics to identify cause-specific biomarkers for chronic kidney disease in a Korean population.Kidney research and clinical practice · 2026Article
- When in doubt, pig it out: a versatile translational platform to study CKD, HFpEF, and CKM syndrome.American journal of physiology. Heart and circulatory physiology · 2025Review
- The Framingham steatosis index as a predictor of advanced CKM syndrome in US adults: Evidence from NHANES 2001 to 2018.Medicine · 2025Article
- Article
- The association of metabolic syndrome components with chronic kidney disease in patients with hypertension: a community-based cohort study.BMC geriatrics · 2025Article
- Transcriptomic Redox Dysregulation in a Rat Model of Metabolic Syndrome-Associated Kidney Injury.Antioxidants (Basel, Switzerland) · 2025Article
- Explainable machine learning model incorporating social determinants of health to predict chronic kidney disease in type 2 diabetes patients.Journal of diabetes and metabolic disorders · 2025Article
- Dynamic changes in metabolic syndrome components and chronic kidney disease risk: a population-based prospective cohort study.BMC endocrine disorders · 2025Article
- Targeting Insulin Resistance and Liver Fibrosis: CKD Screening Priorities in MASLD.Biomedicines · 2025Article
- The prognostic significance of stress hyperglycemia ratio in evaluating all-cause and cardiovascular mortality risk among individuals across stages 0-3 of cardiovascular-kidney-metabolic syndrome: evidence from two cohort studies.Cardiovascular diabetology · 2025Article
- Metabolic health in the Slovenian national cohort of kidney transplant patients.Clinical nephrology · 2025Article
- Certain Metabolic Syndrome Component Combinations are Linked to Increased Risk of Hypogonadism in Taiwanese Men.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Impact of metabolic abnormalities on the association between normal-range urinary albumin-to-creatinine ratio and cardiovascular mortality: evidence from the NHANES 1999-2018.Diabetology & metabolic syndrome · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a term used to denote a combination of selected, widely prevalent cardiovascular disease (CVD)-related risk factors. Despite the ambiguous definition of MetS, it has been clearly associated with chronic kidney disease markers including reduced glomerular filtration rate, proteinuria and/or microalbuminuria, and histopathological markers such as tubular atrophy and interstitial fibrosis. However, the etiological role of MetS in chronic kidney disease (CKD) is less clear. The relationship between MetS and CKD is complex and bidirectional, and so is best understood when CKD is viewed as a common progressive illness along the course of which MetS, another common disease, may intervene and contribute. Possible mechanisms of renal injury include insulin resistance and oxidative stress, increased proinflammatory cytokine production, increased connective tissue growth and profibrotic factor production, increased microvascular injury, and renal ischemia. MetS also portends a higher CVD risk at all stages of CKD from early renal insufficiency to end-stage renal disease. Clinical interventions for MetS in the presence of CKD should include a combination of weight reduction, appropriate dietary modification and increase physical activity, plus targeting of individual CVD-related risk factors such as dysglycemia, hypertension, and dyslipidemia while conforming to relevant national societal guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.